Evidence map›Paper›PMID 34467306›Full record

ArticleJACS Au2021

Synthetic Control of Mitochondrial Dynamics: Developing Three-Coordinate Au(I) Probes for Perturbation of Mitochondria Structure and Function.

R Tyler Mertens, William C Jennings, Samuel Ofori, Jong Hyun Kim, Sean Parkin, Gunnar F Kwakye, Samuel G Awuah

Abstract read
In one paragraph

Article in JACS Au, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. A gold-based inhibitor of oxidative phosphorylation is effective against triple negative breast cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Chiral gold(III) complexes: speciation,Chemical communications (Cambridge, England) · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

R Tyler MertensDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
William C JenningsDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Samuel OforiDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Jong Hyun KimDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Sean ParkinDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Gunnar F KwakyeDepartment of Neuroscience, Oberlin College, Oberlin, Ohio 44074, United States.
Samuel G AwuahDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID 0000-0003-4947-7283

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7M
NCI NIH HHS P30 CA177558NIGMS NIH HHS P20 GM130456
6 · The paper itself

Abstract

Mitochondrial structure and organization is integral to maintaining mitochondrial homeostasis and an emerging biological target in aging, inflammation, neurodegeneration, and cancer. The study of mitochondrial structure and its functional implications remains challenging in part because of the lack of available tools for direct engagement, particularly in a disease setting. Here, we report a gold-based approach to perturb mitochondrial structure in cancer cells. Specifically, the design and synthesis of a series of tricoordinate Au(I) complexes with systematic modifications to group 15 nonmetallic ligands establish structure-activity relationships (SAR) to identify physiologically relevant tools for mitochondrial perturbation. The optimized compound,

Identifiers

PMID34467306
PMCPMC8395693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.